Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 48Neoplasms 13Sarcoma 10Neoplasm Metastasis 9Triple Negative Breast Neoplasms 8Carcinoma, Non-Small-Cell Lung 5Sarcoma, Ewing 2Rhabdomyosarcoma 2Prostatic Neoplasms 2Colorectal Neoplasms 2Urinary Bladder Neoplasms 1Unspecified Adult Solid Tumor, Protocol Specific 1Recurrence 1Peripheral Nervous System Diseases 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Ovarian Neoplasms 1Metastatic HER2-positive Breast Cancer 1Meningeal Neoplasms 1Meningeal Carcinomatosis 1Melanoma 1Lymphoma 1Lung Neoplasms 1Inoperable Locally Advanced HER2-Negative Breast Cancer 1HR+HER2- Breast Cancer 1HER2-low Breast Cancer 1Diabetes Mellitus, Insulin-Dependent, 12 1Carcinoma, Transitional Cell 1Carcinoma, Renal Cell 1Carcinoma, Hepatocellular 1Carcinoma 1

Interventions

eribulin 1Vinorelbine 1Gemcitabine 1Capecitabine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × HR+HER2- Breast Cancer × eribulin × Clear all
NCT06343948 2026-04-17

A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Unresectable Locally Advanced, Recurrent, or Metastatic HR+HER2- Breast Cancer(PANKU-Breast01)

Sichuan Baili Pharmaceutical Co., Ltd.

Phase 3 Active not recruiting
383 enrolled
Breast

HR+HER2- Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡